May 22, 2015

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE RESEARCH LEADS TO FDA APPROVAL OF FIRST DRUG TO TREAT RADIATION SICKNESS




Results Lead to Groundbreaking Decision from Federal Agency

(May 22, 2015)  As a result of research performed by scientists at the University of Maryland School of Medicine (UM SOM), the U.S. Food and Drug Administration has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neupogen®, is the first ever approved for the treatment of acute radiation injury.

The research was done by Thomas J. MacVittie, PhD, professor, and Ann M. Farese, MA, MS, assistant professor, both in the University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology’s Division of Translational Radiation Sciences. The investigators did their research in a non-human clinical model of high-dose radiation.


read FDA press release >>